NCT05496465Phase 2Completed

Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria Flares

Study sponsor: ARS Pharmaceuticals, Inc. · SPRY

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2024-02-29Actual
Enrollment · participants21Actual
Source updated2026-04-07Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Effect of ARS-1 versus placebo based on a patient reported pruritus/hive score. After: Measure: Effect of ARS-1 Versus Placebo Based on a Patient Reported Pruritus/Hive Score.

Actual enrollment decreased by 3 participants

Before: 24 participants (actual). After: 21 participants (actual).

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview